BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27869447)

  • 1. [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
    Vošmiková H; Ryška A; Sieglová K; Laco J
    Cesk Patol; 2016; 52(4):210-214. PubMed ID: 27869447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
    Badoer C; Garrec C; Goossens D; Ellison G; Mills J; Dzial M; El Housni H; Berwouts S; Concolino P; Guibert-Le Guevellou V; Delnatte C; Del Favero J; Capoluongo E; Bézieau S
    Oncotarget; 2016 Dec; 7(49):81357-81366. PubMed ID: 27793035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
    BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
    Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
    Enyedi MZ; Jaksa G; Pintér L; Sükösd F; Gyuris Z; Hajdu A; Határvölgyi E; Priskin K; Haracska L
    Oncotarget; 2016 Sep; 7(38):61845-61859. PubMed ID: 27533253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 8. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
    Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M
    Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].
    Löser H; Heydt C; Büttner R; Markiefka B
    Pathologe; 2017 Mar; 38(2):117-126. PubMed ID: 28258387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.
    Endris V; Stenzinger A; Pfarr N; Penzel R; Möbs M; Lenze D; Darb-Esfahani S; Hummel M; Sabine-Merkelbach-Bruse ; Jung A; Lehmann U; Kreipe H; Kirchner T; Büttner R; Jochum W; Höfler G; Dietel M; Weichert W; Schirmacher P
    Virchows Arch; 2016 Jun; 468(6):697-705. PubMed ID: 27003155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
    Gornjec A; Novakovic S; Stegel V; Hocevar M; Pohar Marinsek Z; Gazic B; Krajc M; Skof E
    BMC Cancer; 2019 Apr; 19(1):296. PubMed ID: 30940100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
    Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
    Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.
    Kluska A; Balabas A; Paziewska A; Kulecka M; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2015 May; 8():19. PubMed ID: 25948282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
    Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
    Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Ion Torrent PGM sequencing workflow for the routine rapid detection of BRCA1 and BRCA2 germline mutations.
    Zanella I; Merola F; Biasiotto G; Archetti S; Spinelli E; Di Lorenzo D
    Exp Mol Pathol; 2017 Apr; 102(2):314-320. PubMed ID: 28263838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
    Ticha I; Kleibl Z; Stribrna J; Kotlas J; Zimovjanova M; Mateju M; Zikan M; Pohlreich P
    Breast Cancer Res Treat; 2010 Nov; 124(2):337-47. PubMed ID: 20135348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
    Rashid MU; Zaidi A; Torres D; Sultan F; Benner A; Naqvi B; Shakoori AR; Seidel-Renkert A; Farooq H; Narod S; Amin A; Hamann U
    Int J Cancer; 2006 Dec; 119(12):2832-9. PubMed ID: 16998791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic.
    Machackova E; Damborsky J; Valik D; Foretova L
    Hum Mutat; 2001 Dec; 18(6):545. PubMed ID: 11748848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.